Abstract: A combination of active agents for the treatment of Lowe Syndrome (LS) comprising a RhoA inhibitor and a mTOR inhibitor; a pharmaceutical composition comprising the combination and a pharmaceutically acceptable carrier; a combination of pharmaceutical compositions in which one composition comprises a RhoA inhibitor and the other composition comprises a mTOR inhibitor; and a method of treating a patient for LS.

Abstract: A combination of active agents for the treatment of Lowe Syndrome (LS) comprising a RhoA inhibitor and a mTOR inhibitor; a pharmaceutical composition comprising the combination and a pharmaceutically acceptable carrier; a combination of pharmaceutical compositions in which one composition comprises a RhoA inhibitor and the other composition comprises a mTOR inhibitor; and a method of treating a patient for LS.

Abstract: A combination of active agents for the treatment of Lowe Syndrome (LS) comprising a RhoA inhibitor and a mTOR inhibitor; a pharmaceutical composition comprising the combination and a pharmaceutically acceptable carrier; a combination of pharmaceutical compositions in which one composition comprises a RhoA inhibitor and the other composition comprises a mTOR inhibitor; and a method of treating a patient for LS.

Abstract: Provided is a method of treating a bladder cancer in an animal or human comprising: administering to an animal or human patient a therapeutic composition comprising a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide and a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain.

Abstract: Provided is a method of treating a bladder cancer in an animal or human comprising: administering to an animal or human patient a therapeutic composition comprising a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide and a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain.

Abstract: The invention provides multivalent fibronectin-integrin binding compositions and methods of use thereof. In certain embodiments, the invention provides peptide compositions that include at least two fibronectin binding peptides coupled together as a cancer therapeutic or a diagnostic tool.

Abstract: Composition and methods are disclosed for utilizing microaggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.

Abstract: Provided is a method of treating a bladder cancer in an animal or human comprising: administering to an animal or human patient a therapeutic composition comprising a first fusion protein capable of specifically binding to an epidermal growth factor receptor (EGFR) on the surface of a cancer cell and comprising an epidermal growth factor (EGF) polypeptide conjugated to a bacterial toxin polypeptide and a second fusion protein comprising an anthrax Lethal Factor N-terminus (LFN) conjugated to a Diptheria Toxin A (DTA) catalytic domain.

Abstract: The invention provides multivalent fibronectin-integrin binding compositions and methods of use thereof. In certain embodiments, the invention provides peptide compositions that include at least two fibronectin binding peptides coupled together as a cancer therapeutic or a diagnostic tool.

Abstract: The invention generally relates to compositions and methods for treating cancer. In certain embodiments, the invention provides methods that involve treating a cancer in a patient in which cancerous cells overexpress epidermal growth factor receptor as compared to non-cancerous cells. The methods involve administering a first composition including anthrax protective antigen modified to bind an epidermal growth factor receptor of a cell, and administering a second composition including anthrax lethal factor N-terminus fused to a catalytic domain of Diphtheria Toxin A. Binding of anthrax lethal factor N-terminus to anthrax protective antigen results in internalization of Diphtheria Toxin A into the cancerous cell, which triggers apoptosis by inactivation of critical elongation factors.

Abstract: Composition and methods are disclosed for utilizing microaggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.

Abstract: Composition and methods are disclosed for utilizing micro-aggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.

Abstract: Composition and methods are disclosed for utilizing micro-aggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.